PDCD1 and cancer: Considering the difficulty in diagnosis of irHAEs due to numerous confounding factors such as the progression of underlying cancer and myelosuppression associated with medications other than a PD-1 or PD-L1 inhibitor, an accurate, reliable prediction model is imperative for early diagnosis and timely intervention of irHAEs [10,20].